ExcelMale
Menu
Home
What's new
Latest activity
Forums
New posts
Search forums
What's new
New posts
Latest activity
Videos
Lab Tests
Doctor Finder
Buy Books
About Us
Men’s Health Coaching
Log in
Register
What's new
Search
Search
Search titles only
By:
New posts
Search forums
Menu
Log in
Register
Navigation
Install the app
Install
More options
Contact us
Close Menu
Forums
General Health & Fitness
Health & Wellness
Anti-Obesity Medications and Investigational Agents
JavaScript is disabled. For a better experience, please enable JavaScript in your browser before proceeding.
You are using an out of date browser. It may not display this or other websites correctly.
You should upgrade or use an
alternative browser
.
Reply to thread
Message
<blockquote data-quote="madman" data-source="post: 240767" data-attributes="member: 13851"><p><strong>Fig. 9. <u>Early versus late weight management intervention</u>: Illustrative consequences. Illustrative potential comparative outcomes for early versus delayed intervention in the evaluation and management of pre-obesity or obesity [84,213–221]. One of the objectives of early pharmacologic intervention for pre-obesity/obesity is to prevent the onset and complications of adiposopathic and fat mass consequences such as diabetes mellitus, hypertension, dyslipidemia, sleep apnea, arthritis, and depression (as well as other adverse health consequences of obesity such as cardiovascular disease and cancer). Lack of early intervention may lead to one or more of these complications, resulting in polypharmacy and the need to follow multiple disease-oriented guidelines.</strong></p><p><strong>[ATTACH=full]27626[/ATTACH]</strong></p><p><strong>[ATTACH=full]27627[/ATTACH]</strong></p></blockquote><p></p>
[QUOTE="madman, post: 240767, member: 13851"] [B]Fig. 9. [U]Early versus late weight management intervention[/U]: Illustrative consequences. Illustrative potential comparative outcomes for early versus delayed intervention in the evaluation and management of pre-obesity or obesity [84,213–221]. One of the objectives of early pharmacologic intervention for pre-obesity/obesity is to prevent the onset and complications of adiposopathic and fat mass consequences such as diabetes mellitus, hypertension, dyslipidemia, sleep apnea, arthritis, and depression (as well as other adverse health consequences of obesity such as cardiovascular disease and cancer). Lack of early intervention may lead to one or more of these complications, resulting in polypharmacy and the need to follow multiple disease-oriented guidelines. [ATTACH type="full"]27626[/ATTACH] [ATTACH type="full"]27627[/ATTACH][/B] [/QUOTE]
Insert quotes…
Verification
Post reply
Share this page
Facebook
Twitter
Reddit
Pinterest
Tumblr
WhatsApp
Email
Share
Link
Sponsors
Forums
General Health & Fitness
Health & Wellness
Anti-Obesity Medications and Investigational Agents
This site uses cookies to help personalise content, tailor your experience and to keep you logged in if you register.
By continuing to use this site, you are consenting to our use of cookies.
Accept
Learn more…
Top